Acute i.v. vincamine teprosilate administration: quantified investigation in elderly subjects.
The EEG changes in elderly subjects with chronic cerebrovascular disorders (CCVD) are well known and have been described by many authors. Vincamine teprosilate (Teproside), a drug supposed to act on the electrical activity of the brain, has the properties of modifying and, to some extent, improving age-related changes. Ten subjects, whose age ranged from 60 to 70 years, underwent the trial. Each received 1 ampoule i.v. of the active drug and 1 ampoule of placebo (or vice versa) after a 48-hour wash-out period, according to a double-blind randomized schedule. EEG recordings were performed at time 0 and then 30 min, 1 h, 2 h, and 4 h after injection. A double effect of vincamine teprosilate could be observed at the quantified EEG: 1) an early effect, i.e., an improvement of the EEG pattern within the first hour following administration; and (2) a slow-occurring effect that prevented negative EEG modifications from taking place at the fourth hour following administration.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000503:physiopathology; D002908:Chronic Disease; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D013997:Time Factors; D014748:Vinca Alkaloids / Q000494:pharmacology*; D014749:Vincamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology*
D014748:Vinca Alkaloids; C038060:vincamine teproside; D014749:Vincamine